This company has two distinct lines of technology to service the best entities in the world-wide Healthcare Sector. However, this is not uncommon in the Biotechnology & Drugs industry. The stock is especially worth owning because the company keeps pressing patient needs in bringing its technology to market. This approach implies that investors can look forward to better Present Value for their stock investing.
Both lines of know-how of this company relate to quick and convenient ways to delivering active therapeutic substances inside patient bodies. The company has concentrated on the inner lining of the human mouth, so its drug delivery systems are most helpful for patients who suffer from cancer, the effects of surgery, and severe pain due to other reasons.
The technology is also relevant for protecting the oral cavity from fungal infections, which is a common problem for patients with impaired immunity. Patients have had to be treated for such fungal injections through painful and inconvenient injections until now. US regulators have approved of the company’s system of drug delivery through the lining of the mouth.
The company has a vast array of important development projects underway for varied applications of both its drug delivery platforms. This includes the important business area of insomnia management, apart from the company’s traditional interests in cancer and fungal treatment. The company also has exclusive right in the United States for marketing a new treatment system for nausea and vomiting.
The stock closed February 25 2008 at $2.53 and appears set to steadily approach its 52-week high of $8.26. It may be one of the best long-term prospects of its kind this industry.
Let us hear your thoughts below:
